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Background: Cerebral palsy is the most common cause of physical disability in childhood. Spasticity is a significant
contributor to the secondary impairments impacting functional performance and participation. The most common
lower limb spasticity management is focal intramuscular injections of Botulinum Toxin-Type A accompanied by
individually-delivered (one on one) physiotherapy rehabilitation. With increasing emphasis on improving
goal-directed functional activity and participation within a family-centred framework, it is timely to explore whether
physiotherapy provided in a group could achieve comparable outcomes, encouraging providers to offer flexible
models of physiotherapy delivery. This study aims to compare individual to group-based physiotherapy following
intramuscular Botulinum Toxin-A injections to the lower limbs for ambulant children with cerebral palsy aged four
to fourteen years.
Methods/Design: An assessor-masked, block randomised comparison trial will be conducted with random
allocation to either group-based or individual physiotherapy. A sample size of 30 (15 in each study arm) will be
recruited. Both groups will receive six hours of direct therapy following Botulinum Toxin-A injections in either an
individual or group format with additional home programme activities (three exercises to be performed three times
a week). Study groups will be compared at baseline (T1), then at 10 weeks (T2, efficacy) and 26 weeks (T3, retention)
post Botulinum Toxin-A injections. Primary outcomes will be caregiver/s perception of and satisfaction with their
child’s occupational performance goals (Canadian Occupational Performance Measure) and quality of gait
(Edinburgh Visual Gait Score) with a range of secondary outcomes across domains of the International Classification
of Disability, Functioning and Health.
Discussion: This paper outlines the study protocol including theoretical basis, study hypotheses and outcome
measures for this assessor-masked, randomised comparison trial comparing group versus individual models of
physiotherapy following intramuscular injections of Botulinum Toxin-A to the lower limbs for ambulant children
with cerebral palsy.
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Cerebral palsy (CP) is the most common cause of physical
disability in childhood with an incidence of 2.11 per 1000
live births [1]. It describes a “group of permanent disorders
of the development of movement and posture, causing ac-
tivity limitations that are attributed to non-progressive dis-
turbances that occurred in the developing fetal or infant
brain” [2]. In 2013, the Australian Cerebral Palsy Register
reported that 71% of children with CP achieved ambulation
and 91% were classified with spasticity as the predominant
motor type. Children with lower limb spasticity often ex-
perience a range of impairments including weakness, tight-
ness, reduced motor control and muscle selectivity. These
impairments can lead to limitations in functional ability,
balance, ambulation and fitness compared to typically de-
veloping peers [3,4]. Physiotherapy intervention focuses on
reducing these impairments and optimising functional,
goal-related performance.
Focal, intramuscular Botulinum Toxin-Type A (BoNT-
A) injections to the lower limb are commonly used in
combination with physiotherapy as the temporary reduc-
tion in spasticity provides an opportunity to facilitate
rehabilitation outcomes [5-8]. For ambulant children
with CP (Gross Motor Functional Classification System,
GMFCS-E&R, Levels I-III [9]), there is strong evidence
that injections of BoNT-A are safe and reduce muscle
tone in spastic, active and non-fibrotic lower limb muscles
for approximately 12–16 weeks [6,7,10-12]. BoNT-A
impacts body structure and function, however the ac-
companying physiotherapy often targets activity level
outcomes (International Classification of Functioning,
Disability and Health, ICF [13]).
Functional improvement in ambulant children with CP
has been reported in a number of randomised controlled
trials (RCTs) comparing intramuscular lower limb BoNT-A
injections with rehabilitation (physiotherapy, casting and/or
orthotic management), to a control group of rehabilitation
alone with or without placebo injections. Rehabilitation
combined with BoNT-A injections demonstrated sig-
nificantly greater improvement in gross motor function
as measured by the Gross Motor Function Measure
(GMFM-88 or-66) [14-18] and quality of gait using the
Physician’s Rating Scale [14,19-22], Edinburgh Visual
Gait Score (EVGS) [23] or Three Dimensional Gait
Analysis (3DGA) [20]. Improvement in performance-
related goals have been reported when measured by the
Canadian Occupational Performance Measure (COPM)
[17], Goal Attainment Scaling (GAS) [24] or parental
questionnaires [15,16,25].
Despite the acknowledged success of physiotherapy re-
habilitation combined with BoNT-A injections, relative
effectiveness of the specific components of physiother-
apy rehabilitation, including intensity and dose, is diffi-
cult to interpret because it is often poorly described[14,15,17,25]. Results of a number of systematic reviews
and consensus papers found limited evidence to support
or refute individual physiotherapy modalities post lower
limb BoNT-A injections [5,7,11,26]. The content of
physiotherapy rehabilitation outlined in reported studies
has included: active and passive stretching of muscle
agonists [16,18,22,23,27]; functional or resistive strength-
ening of the antagonists [16,18,22,23,27]; functional mo-
bility training and/or gait training [16,18,23,27]. One
retrospective, controlled intervention study has directly
compared the specific content of two physiotherapy
approaches following lower limb BoNT-A injections
[28]. Thirty-eight children with CP (mean age 7 years, 7
months, GMFCS I-III, 11 unilateral, 27 bilateral motor
distribution) who received Neurodevelopmental Treat-
ment (NDT, mean total dose 24.2 hours) were randomly
selected and retrospectively matched to a group of chil-
dren who received conventional physiotherapy (CPT,
mean total dose 20.5 hours). Content of physiotherapy,
determined via therapist questionnaires, and improve-
ment of impairment and gait-related goals (GAS) were
compared between groups two months post injection.
Both approaches utilized muscle tone inhibition tech-
niques, stretching, strengthening and functional train-
ing, with the NDT group spending a greater proportion
of time on functional training (NDT 42%; CPT 28%,
p = 0.009). Whilst the NDT group showed greater goal
attainment post intervention (mean converted GAS score
NDT 56, CPT 52, p = 0.008), results should be interpreted
cautiously. Therapy content was only described and ana-
lysed for 62% (n = 47) of children due to reduced comple-
tion of questionnaires by treating physiotherapists. As GAS
goals were impairment-based it is unclear from this study
if a more functional approach to training translates to
improvement in goals related to function and participation.
In the absence of high level evidence, expert opinion
and consensus statements recommend post BoNT-A
physiotherapy includes functional and targeted motor
training in combination with serial casting, stretching
and strengthening [7,8,29]. Additionally, intervention
should incorporate: (1) collaborative, individualized,
realistic and specific goal setting which span across all
domains of the ICF [7,29]; (2) specificity of task and
training [30,31]; (3) repetition and practise within a
functional “just right” context [32,33]; (4) environmental
adaption [34] and (5) strategies to increase motivation
and engagement [35,36]. This approach will facilitate re-
habilitation focused on each child’s specific goals and
functional needs [6,33,37]. Studies investigating the effi-
cacy of physiotherapy combined with BoNT-A injec-
tions have consistently included therapy delivered in an
individual model. It is unclear whether similar outcomes
could be achieved using alternative methods of physio-
therapy delivery.
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the literature for children with CP including: (1) individual
(one on one); (2) group-based (three or more participants
with similar abilities [38]); (3) web-based training or
virtual reality [39,40]; (4) individual consultation with
intervention performed as a home programme [41].
Group-based training has been shown to achieve posi-
tive rehabilitation outcomes through maximising en-
gagement, motivation and participation [36,42]. Relative
effectiveness of group versus individual physiotherapy
post lower limb BoNT-A injections has not been exam-
ined to date, however. Independent of BoNT-A, effect-
iveness of group versus standard individualised care has
been compared for ambulant children with CP receiving
strength, endurance and fitness training [43,44], pro-
gressive functional strength training [45,46] and goal-
directed activity-focused physiotherapy [47]. Results are
difficult to compare due to the heterogeneity of theoret-
ical focus, therapy dose and outcome measures used.
However, these studies provide useful guidelines for the
elements that contribute to successful group-based
physiotherapy.
Effective group-based physiotherapy interventions re-
port similar session structure including warm up, spe-
cific intervention activities and then warm down. To
maintain motivation and specificity of practise, a com-
bination of group-based activity and individual or paired
circuit activity has been recommended [43,44,46,47]. To
ensure adequate supervision and progression of exer-
cises, group sizes have been limited to small (4–6
children) [44,45,47] or medium (7–9 children) [43]. Ef-
fective dose is not well understood due to variability in
intensity, frequency and duration of intervention. Total
direct therapy dose has varied from 36 hours [43,45] to
70 hours [44], delivered in varying intensity from three
week blocks (intensive model) [47] to 34.6 weeks (dis-
tributed model) [44]. Individual session duration has
ranged from 45 to 180 minutes with a frequency of
two to five sessions per week. Indirect treatment dose
achieved via home programme is difficult to interpret
due to inadequate reporting. Despite insufficient evi-
dence to confirm optimal group format, several studies
found that group-based therapy can achieve equal or
greater improvement in outcomes across ICF domains
when compared to individual standard care. These in-
clude improvements in gross motor ability (GMFM-66)
[43,44,47], crouch gait (3DGA) [48], participation (Chil-
dren’s Assessment of Participation and Enjoyment:
CAPE) [44], health-related quality of life (TACQOL)
[44] and goal attainment (GAS) [47]. One RCT (n = 51)
compared group-based progressive resistance exercise
strength training to individualised standard care in 51
ambulant children with CP (GMFCS I-III; mean age 10y
5mo, SD 1y 10mo; 29 male) [45,46]. This study reportedno improvement in either group for gross motor ability
(GMFM-66), walking ability (One Minute Fast Walk
Test) or participation (CAPE). No studies have reported
inferior outcomes for group-based interventions com-
pared to individual standard care. Additional qualitative
benefits of a group-based model have been reported in the
context of the self-determination theory [49,50]. A group
program may enhance self-regulation and engagement
in the therapy process by attending to children’s basic
psychological needs for Autonomy, Relatedness and
Competence. There is potential for greater promotion
of autonomy by allowing choice (personal goal setting),
and through enjoyment, having fun and behaviour mod-
elling to master activities [36,51]. A sense of compe-
tence may be fulfilled through scaffolding activities to
promote skill development, and providing opportunities
for peer learning [52-54] and healthy competition
[30,36]. Social support and working with children with
similar needs may also increase the feeling of related-
ness [36,55].
A group model has the potential to meet the physio-
therapy rehabilitation needs for children post lower limb
BoNT-A injections. To date there has been no study that
has directly compared dose and content-matched group
versus individual models of functional, goal-directed
physiotherapy rehabilitation following lower limb BoNT-
A injections for ambulant children with CP. This study
aims to compare the efficacy of these two models to en-
able informed choice of post BoNT-A physiotherapy re-
habilitation delivery.Methods/Design
Study aims
This assessor-masked, parallel group, block RCT aims
to compare group versus individual models of physio-
therapy following intramuscular lower limb injections of
BoNT-A for ambulant school-aged children with CP in
the ICF domains of impairment (quality of gait, func-
tional reach), activity/participation (caregiver/s percep-
tion of and satisfaction with their child’s occupational
performance, gross motor function, walking efficiency)
and quality of life [13]. A secondary aim is to gain qualita-
tive feedback from treating physiotherapists, caregivers
and participants involved in the study to determine ac-
ceptability of the two treatment models.
Study hypotheses are based on the reported benefits of a
group model being at a participation and contextual level,
so outcomes reflecting a child’s occupational performance,
participation or quality of life may improve more in the
group-based intervention. Individual training has the po-
tential for greater intensity, specificity of training and
repetition of practise of skills. Outcomes at the body,
structure and function or activity level [13] could improve
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hypotheses to be tested are:
Primary hypotheses
H1: Compared to individual physiotherapy, group physio-
therapy will result in greater improvement in caregivers’
perception of performance of and satisfaction with their
child’s occupational goal areas (COPM). This will be ob-
served as between group differences of two or more COPM
performance and satisfaction points at T2 (10 weeks-effi-
cacy) and T3 (26 weeks-retention) [56].
H2: Compared to group physiotherapy, individual physio-
therapy will result in greater improvement in quality of
gait (mean score change of ≥ 4.0 points on the Edinburgh
Visual Gait Score) at T2 (10 weeks-efficacy) and T3
(26 weeks-retention) [57-59].
Secondary hypotheses
H3: Compared to group physiotherapy, individual physio-
therapy will result in greater improvement in efficiency of
gait (One Minute Fast Walk Test [60]), gross motor per-
formance (Gross Motor Function Measure-88 Items D&E
[61,62]) and functional balance (forward component of
the Pediatric Reach Test [63]) at T2 (10 weeks- efficacy)
and T3 (26 weeks- retention).
H4: Compared to individual physiotherapy, group physio-
therapy will result in greater improvement in quality of life
(Cerebral Palsy Quality of Life Questionnaire). This will
be observed as a between group difference of five points
or more in each domain at T2 (10 weeks- efficacy) and T3
(26 weeks- retention) [64-67].
Study sample and recruitment
Inclusion criteria
The study will include children who:
1. Are aged 4–14 years at study entry;
2. Have a confirmed diagnosis of CP with a
predominant motor type of spasticity;
3. Are ambulant (classified GMFCS-E&R Level I-III);
4. Are patients of the Queensland Cerebral Palsy
Health Service (CP Health) BoNT-A program;
5. Require lower limb BoNT-A for management of
spasticity interfering with lower limb functional goals;
6. Can commit to six weekly sessions of post-BoNT-A
physiotherapy in either a group or individual format.
Exclusion criteria
Children will be excluded from the study if they:
1. Are unable to complete baseline assessments;
2. Have had orthopaedic or neurological surgery and/
or other new spasticity management (e.g. Baclofen)
within six months prior to commencing the study;3. Have intellectual or behavioural difficulties which
would limit their ability to participate in the
assessment or therapy protocols;
4. Have medical co-morbidities which prevent them
from exercising safely (e.g. cardiac or respiratory
instability, uncontrolled seizures).
Criteria for withdrawal/failure to proceed
Children will be classified as failure to proceed if they do
not attend a minimum of four hours of direct therapy
(>66%), or if they need to be withdrawn from the study
due to significant post-injection or other medical complica-
tions requiring deviation from the rehabilitation pathway.
Recruitment
Sample size
According to CONSORT guidelines, the sample size cal-
culation is based on adequate power for comparison be-
tween the functional effects of group-based and individual
physiotherapy intervention at 10 weeks (T2, immediately
post intervention). A change score difference of two or
more points between groups on the performance scale of
the COPM (primary outcome measure) would be consid-
ered clinically meaningful [56]. A previous study of lower
limb intramuscular injections of BoNT-A yielded a stand-
ard deviation of changes of 1.4 and 1.7 for COPM per-
formance [17]. Based on a mean change of two points on
the COPM performance scale and a standard deviation of
1.6 points for both groups, significance (alpha) level of
0.05 and 80% power, we require 24 participants (12 in
each group). Allowing for 20% drop out, a total of 30 par-
ticipants (15 in each group) will be recruited.
Randomisation
Eligible children will be recruited prospectively from the
Queensland CP Health Service (Brisbane, Australia)
BoNT-A injecting lists in blocks of four to eight chil-
dren. For each recruitment period, participants will be
evenly distributed into one of two geographical clusters
according to residential address. Each cluster will be
allocated to group or individual therapy by concealed
random allocation. The random sequence will be cre-
ated via coin flipping by an off-site, non-study re-
searcher masked to all other study data. The outcome
(e.g. 1 = group; 2 = individual) will be written on a piece
of paper and concealed inside a sequentially numbered
envelope and securely stored off-site. At each recruit-
ment period the study coordinator will contact the off-
site researcher to open the next consecutive envelope to
reveal treatment allocation. At the end of each recruit-
ment period, there will be close to equal numbers of
children in each study arm. This process will continue
until 30 participants are recruited.
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Refer to Figure 1 for the study flow diagram according
to CONSORT guidelines.Figure 1 GRIN flow chart according to CONSORT guidelines. Legend: C
Toxin- Type A; EVGS: Edinburgh Visual Gait Scale; PRT: Pediatric Reach Test;
Minute Fast Walk Test; GMFM-88 D&E: Gross Motor Function Measure-88, It
PTs: Physiotherapists; HEP: Home Exercise Programme.Stage 1: Botulinum Toxin-A injection/s
In accordance with current standard clinical practice, the
rehabilitation consultant and physiotherapist will determineP Health: Queensland Cerebral Palsy Health Service; BoNT-A: Botulinum
COPM: Canadian Occupational Performance Measure; 1MFWT: 1
ems D&E; CPQOL-Child: Cerebral Palsy Quality of Life Questionnaire;
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assessment and consultation with the child and their care-
giver/s. Muscle selection will vary between participants
according to spasticity-related functional impairment
and goals of the child and family, as well as from clinical
assessment of: gait characteristics (observational gait ana-
lysis); resistance to passive stretch (Modified Ashworth
Scale [68]); spasticity and dynamic range of movement
(Modified Tardieu Scale [69]) and passive range of move-
ment (goniometric and angle finder measures [70]). Dose
of BoNT-A will be prescribed according to the Consensus
Opinion of the ‘We Move’ Spasticity Study Group (2002),
up to a maximum dose of 16 U/kg/body weight, or to a
total maximum dose of 400 Units of Botox® (Allergan
PLC). Children will receive injections either in theatre
under general anaesthetic (100U Botox® diluted in 2 mls
of normal saline), or as an outpatient using EMLA cream
at the injection site/s (100 U Botox® diluted in 1 ml of
normal saline).
Stage 2: Serial casting and orthotic prescription
Serial casting will be provided within the three weeks
following BoNT-A injections to children with a compo-
nent of fixed equinus contracture (less than neutral/0
degrees of passive range of ankle dorsiflexion with the
knee extended) [7]. Casting will be performed until at
least neutral dorsiflexion is achieved. Dose comparisons
between study arms will be analysed retrospectively from
patient records. Orthoses will be prescribed or modified
for each participant by an orthotist as clinically indicated.
Moulding for orthoses will occur immediately post BoNT-
A for children not requiring casting, and on the day of the
last cast fitting for those receiving casting. All orthoses
will be available prior to commencement of the rehabilita-
tion block.
Stage 3: Physiotherapy intervention
Direct therapy dose for both group and individual models
of physiotherapy will be one 60 minute session per week
for six weeks (total dose six hours), which is consistent
with current funded clinical practice in Queensland. Indir-
ect therapy dose will involve each participant performing
three additional individualised, goal-directed activities at
home three times a week. Participants will be asked to ab-
stain from any other interventions (e.g. occupational ther-
apy, aquatic therapy) during the rehabilitation phase but
can return to their usual therapy following the interven-
tion program. Any therapy or additional structured activ-
ity completed during the study will be recorded via a
custom-designed questionnaire.
Individual therapy Participants in the individual arm of
the study will receive physiotherapy on a one-to-one basisfrom their usual physiotherapist, who may be located in
either a hospital or community out-patient setting.
Group therapy Each group will include at least three
participants [38]. If there are insufficient participants to
form a group for any recruitment block, additional chil-
dren with CP (not involved in the study) will be invited
to participate. Each additional child will need to meet all
study inclusion criteria except they will not have received
recent lower limb BoNT-A injections. As for individual
rehabilitation, group rehabilitation will be provided in hos-
pital or community settings at a location mutually con-
venient for each geographical cohort. Group sessions will
be directed by one lead physiotherapist with assistance
from additional physiotherapist/s, allied health assistant/s
or physiotherapy student/s to achieve a minimum ratio of
one therapist to three participants. Group dynamics will
be encouraged in a variety of ways. For example, children
will decide on a name for their group, agree on group
rules, receive a team “t-shirt” to wear during sessions and
be involved in choosing a theme for the group each week.
Activities such as warm up, warm down, stretching and
circuit stations will include a combination of group or
paired formats. The overall ratio will include a mini-
mum of 60% exercises performed as a group or paired
activities and 40% exercises performed simultaneously
in a circuit format.
Content of physiotherapy intervention
Content of the physiotherapy protocol is based on a re-
view of the literature and a clinical practice audit of post
BoNT-A rehabilitation providers in Queensland. Exer-
cises have been chosen that require minimal specialised
equipment to enable consistent delivery of the program
across hospital and community settings. To ensure ses-
sion structure is the same across both physiotherapy
models, a program of suitable exercises and progressions
will be provided to treating physiotherapists. Therapists
will select and modify exercises to suit each child’s age, in-
trinsic motivators, individual goals and progression rate.
An outline of the session format is displayed in Table 1.
Home exercise programme (HEP)
One key researcher (RT) will design an individualised
HEP for each participant. Activities will include part or
full task practise of each participant’s key functional
goals as identified from the COPM. After the first week,
the treating physiotherapist will incrementally progress
the HEP activities in liaison with the key researcher as
required. Caregivers and/or children will be asked to
record the dates, duration and number of repetitions of
each activity performed as a HEP, as well as involvement
in concurrent activities and/or therapy.





Theoretical rationale Activity examples
Warm up activities 5 Activities have been chosen to prepare the child’s
mind and body for the therapy session. In the
group model, dynamics will be encouraged by
performing games/activities as a group.
• Animal and yoga postures




10 Exercises have been selected to mobilize lower limb
joints and muscles through the available range
using sustained stretching of agonists injected with
BoNT-A for a minimum of five repetitions of 30
seconds duration [71,72].
• In paired long sitting facing each other with feet
together, pass the ball between each other
(hamstring stretch)
• Heel dips off the edge of a step (calf stretch)





5 Repetitive, weight-bearing activities have been
chosen to improve muscle strength required for
functional activities that reflect goals identified via
the COPM [36,44]. The focus is on concentric and
eccentric muscle activity using body weight resist-
ance. Intensity will be specific to each individual,
aiming for 70% of maximum effort, with progres-
sion occurring through increasing the number of
repetitions or the difficulty of the task (e.g. lower
the height of the chair for sit to stand; increase the
height of the step for step-ups; increase the speed
to complete the activity). Three sets of 10 repeti-
tions is the aim for all participants [73-75].
• Sit to stand
• Squat to stand





5 Activities have been selected to improve the limits
of stability in standing tasks relevant to balance
goals identified on the COPM.
• Activities in standing where the participant has to
reach or squat for an object outside the base of
their support
• Games standing on one leg (SLS) with/without





5 Individualised activities will be set for each
participant to facilitate task practise of functional
goals identified on the COPM. Repetition/practise
and incremental progression of tasks will occur
each week, and through the home programme, to
reinforce motor learning [76].
• SLS activities +/− support e.g. dribble ball around
standing foot.
• Kicking to goal (start with large goal area and
gradually decrease size).
Goal example:
• Kick ball between 2 people (start with larger ball,
decreasing to age appropriate size; progress to
kicking ball further to side and increase speed).
Improve XX ability to kick the ball when playing
soccer with friends at school
• Be able to make contact with the ball 8 out of
10 attempts
• Improve accuracy of kicking to a target (5/10
successful attempts)




5 Activities or games will be carried out to challenge
and improve participants’ agility and fitness, aiming
for carry-over into physical activity goals (such as
being able to run in the playground during school
breaks without needing to sit down to rest).





5 Children will participate in activities that continue
to mobilise muscles through range to maximise
flexibility, prevent muscle soreness and injury, as
well as facilitate reduction in heart rate and
temperature to ensure they are in a less aroused
state prior to leaving therapy.
• Yoga
• ‘Simon Says’
• Songs with actions
Review of home
programme
10 Review of home programme with each caregiver
and participant.
Includes incrementally progressing activities related
to the functional performance goals (COPM).
Key: BoNT-A: Botulinum Toxin-Type A; COPM: Canadian Occupational Performance Measure; SLS: single leg stance.
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Physiotherapists providing intervention (group and indi-
vidual) will be masked to baseline outcome assessments.
They will require a minimum of two years’ experience in
providing post BoNT-A rehabilitation for children with
CP in association with CP Health. In addition, before and
during the study, each therapist (and assistants as rele-
vant) will receive face to face or telephone education from
the study coordinator (RT) regarding intervention format,
content, roles of different staff, exercise and HEP progres-
sion. At the start of each rehabilitation block, treating
physiotherapists will be provided with standard informa-
tion for each relevant participant, including the BoNT-A
injection date, dose and site/s, baseline musculoskeletal
assessment and goals (without score) identified through
the COPM. A copy of the physiotherapy protocol will
also be provided with suggestions of activities to include
in the targeted motor control station, based on each
relevant participant/s individualised goals. Physiothera-
pists will complete a session evaluation form for every
participant after each of the six sessions. This includes a
summary of activities completed including proportion
of time taken on each task. Independent content ana-
lysis will determine compliance with the protocol across
both arms of the study.
Outcome measures and procedures
1. Classification of the sample
Participants entered into the study will be classified
according to:
a) Gross Motor Functional Classification System
(GMFCS-E&R: [9]):
The GMFCS-E&R is an internationally recog-
nized classification scale for gross motor abilities
in children with CP aged two to 18 years ranging
from Level I (able to walk independently with
limitations in higher gross motor skills) to Level
V (unable to sit alone). All children in this study
will be ambulant, classified as Levels I-III.
b) Classification of cerebral palsy:
Participants will be classified according to motor
type/s (primary spasticity), number of limbs
involved and unilateral or bilateral distribution
[77,78].
c) Functional mobility: Functional Mobility Scale
(FMS)
The FMS was designed for children with CP aged
four to eighteen years and rates assistive devices
required and walking ability at five, 50 and 500
metres which correlate with the child’s ability in
the home, school and community settings. The
scale ranges from N= does not apply; C = crawling;
1 = uses wheelchair; 2 = uses walker or frame;3 = uses crutches; 4 = uses sticks (one or two);
5 = independent on level surfaces; 6 = independent
on all surfaces [79].2. Outcome measures
Outcome measures will be administered by one
physiotherapist (MK) trained and experienced in
performing all assessments and one Allied Health
Assistant (One Minute Fast Walk Test only). Both
assessors will be masked to treatment allocation and
previous assessment data. Assessments will be
performed at baseline (T1: 0–2 weeks pre BoNT-A
injection/s), 10–12 weeks post BoNT-A (T2: on
completion of the six week rehabilitation block,
efficacy) and at 26 weeks post BoNT-A (T3) to
determine medium-term retention of effects. Assess-
ment timeframes are depicted in Figure 1. A range
of outcome measures will be used across domains of
the ICF [13].
2.1 Body functions and structures2.1.1 Quality of gait: Edinburgh Visual Gait
Score for Cerebral Palsy (EVGS)
Competence of motor control during gait
will be compared to normal values using
the EVGS and will be a primary outcome
measure for this study. The EVGS is a
tabulated scoring system that records 17
joint angles or movements of the trunk and
lower limbs during a representative stride.
EVGS total score ranges from 0 (best) to 68
(worst) [57]. The EVGS has excellent
criterion validity (64% agreement with
instrumented gait analysis), repeatability
(least significant difference = 3.20 points)
and sensitivity to change following surgical
intervention (minimal clinically important
change: mean score reduction of 4.2 points,
range +0.3-8.5) [57-59]. It has good intra-
observer reliability which is higher with
more experienced observers [23,57,80,81].
Split screen gait analysis will be videotaped
simultaneously in the sagittal and frontal
planes at the Queensland Children’s Gait
Laboratory (QCGL) and independently
scored off-site by one physiotherapist (LJ)
experienced in EVGS scoring and masked
to group allocation, order of assessment and
previous data.
2.1.2 Functional balance The Pediatric Reach
Test (PRT)
To evaluate the limits of stability in free
standing, the forward component of the
PRT will be used [63]. In this test, the
participant stands with their feet on a line
with their dominant arm outstretched at 90
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Paper is fixed to the wall at the side of the
participant who touches the wall laterally to
make a mark on the paper at the starting
position. The participant is then instructed
to reach as far forwards as possible without
moving their feet or losing balance. A
second mark on the paper is made at this
point. The reach is measured as the mean
distance reached on three attempts.
Correlations between the PRT in standing
and laboratory tests of limits of stability is
moderate-to-high (r = 0.42 to 0.77). For
children with CP, test-retest reliability and
interrater reliability range from intraclass
correlation coefficients (ICC) of 0.54 to 0.88
and 0.50 to 0.93, respectively [63,82].2.2. Activity and participation outcomes
2.2.1 Goal attainment: Canadian Occupational
Performance Measure (COPM)
The COPM [56,83,84] identifies concerns
regarding occupational performance and
documents changes post BoNT-A rehabili-
tation [29] and will be a primary outcome
measure in this study. It has demonstrated
high re-test reliability (ICC 0.76-0.89),
sensitivity to change and good content,
construct and criterion validity for children
with CP receiving BoNT-A [17,85-87]. The
COPM will be administered using a semi-
structured interview in collaboration with
the caregiver/s and participant (dependent
on age, cognitive ability and motivation to
contribute) [88]. The child-adapted model
has three sections: self-care (personal care,
functional mobility and community man-
agement), productivity (play/school) and
leisure (quiet recreation, active recreation
and socialisation). Caregivers will be asked
to identify three daily activities of concern
where they or their child hope to improve
after lower limb BoNT-A injections [17,85].
They will rate their perception of their
child’s performance and their satisfaction
with this performance on a 1–10 ordinal
scale. A score change of two or more points
is considered clinically significant [56].
2.2.2 Efficiency of gait: The One Minute Fast
Walk Test (1MFWT)
The 1MFWT is considered a good
discriminator of functional ability for
dynamic balance, muscle performance and
endurance [60]. The test involves a five
minute rest, followed by walking for oneminute around a 20 metre oval track at
maximum walking speed without running.
Children are able use normal walking aids
and wear orthoses. Distance is calculated to
the nearest metre. The 1MFWT shows
concurrent validity with the GMFM with a
significant correlation between GMFM-88
score and distance walked (r = 0.92)
[60]. Reliability has been established
(ICC = 0.97, Standard Error of Measure-
ment, SEM =4.0 m (4.1%)) with a score
change of >17% (mean 1.28 m/s, SD 0.42)
considered clinically meaningful [46].
2.2.3 Gross motor ability: Gross Motor Function
Measure (GMFM-88)
The GMFM-88 is a criterion-referenced
measure designed for children with CP aged
0–18 years to assess motor function in five
areas [61,62]. Items D (standing) and E
(walking, running and jumping) will be
administered as study participants are
ambulant with goals frequently reflected in
these areas. The GMFM-88 has good intra-
rater (ICCs 0.92-0.99) and interrater (ICCs
0.87-0.99) reliability [61] and demonstrated
validity to reflect change in gross motor
function over time (ICCs 0.66-0.79) [89]. A
ceiling and floor effect has been reported
which highlights caution when interpreting
results [61,90]. A change score of 1.3 points
(total score), 1.2 points (Dimension D) and
1.6 points (Dimension E) is considered
clinically meaningful [91,92]. A change
score of 3.99 points further separates a
great improvement from moderate or no
improvement [91].
2.3 Contextual
2.3.1 Quality of life: The Cerebral Palsy Quality
of Life Questionnaire (CPQOL-Child and
CPQOL-Teen)
The CP QOL-Child [64-66] and the CP
QOL-Teen [67] are quality of life assess-
ments designed for children and adolescents
with CP aged four to 12 years and 13 to 18
years respectively. Both quantify well-being
across seven key quality of life domains
relevant to age group. Items are scored on a
nine point rating scale, then summed and
averaged to generate seven domain scores.
The primary caregiver proxy versions will
be used in this study as it is anticipated that
the majority of children will be less than
nine years of age. The CPQOL-Child
and -Teen (primary caregiver proxy
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consistency (−Child: ICC 0.74-0.92; -Teen:
Cronbach’s alphas 0.81-0.96), test–retest
reliability (−Child: ICC 0.76-0.89; -Teen:
ICC 0.29-0.83) and adequate construct
validity supported by the pattern of correla-
tions with scales including the Child Health
Questionnaire (−Child only), Pediatric
Quality of Life Inventory (−Teen only),
KIDSCREEN and GMFCS [66,67].
2.3.2 Qualitative evaluation
i.) Caregiver, child and physiotherapist
satisfaction
Post intervention (T2), custom-designed
questionnaires will be used to evaluate satis-
faction with the physiotherapy rehabilitation
format. Questions will be open-ended and
answers reviewed by one co-investigator
(RT) to determine consistent themes.
ii.)Child’s motivation and engagement with
the physiotherapy intervention
To evaluate whether there is a relationship
between study outcomes and participant’s
performance in therapy sessions, treating
physiotherapists will be asked to rate each
participant’s motivation, engagement and
compliance with the physiotherapy
exercises after each session using
custom-designed five point Likert Scales.
iii.) Child’s ongoing activity levels and
maintenance of goals
At six months post BoNT-A (T3), each
caregiver will complete a custom-designed
questionnaire to report their child’s access
to ongoing therapy, completion of HEP,
structured and un-structured activities, as
well as caregiver’s perception of mainten-
ance of goal areas on a ten point Likert
Scale.3. Adverse events
Treating physiotherapists will record any adverse
events following each physiotherapy session.
Adverse events will be classified as: Mild: awareness
of sign or symptom, but easily tolerated; Moderate:
discomfort enough to cause interference with usual
activity; Severe: incapacitating with inability to do
usual activity. Standard reporting and follow-up will
be adhered to as per current Queensland Health
protocol.
Analyses
Statistical analysis will be undertaken by an investigator
masked to group allocation (LS). Primary analysis will use
the intention to treat principle, using the last observationcarried forward for participants who withdraw before the
end of the trial. Baseline data from each outcome measure
for each treatment group will be reported using descrip-
tive statistics. Continuous data will be compared between
groups by fitting a regression model using generalized
estimating equations [93] to baseline, 10 and 26 week
measurements with an interaction term between the
intervention group and a three-level factor indicating
time of measurement. The generalized estimating equa-
tion model will assume a Gaussian family, identity link,
and unstructured working correlation matrix for repeated
measurements on participants. Conventional variance es-
timates will be used. Where continuous data exhibit skew-
ness not overcome by transformation, non-parametric
methods (Mann–Whitney U) will be used for simple com-
parisons. Statistical significance will be at p < 0.05 and
analyses will be performed using STATA 11.
Discussion
This protocol paper presents the background and design
of an assessor-masked, randomised comparison trial
evaluating the efficacy of group versus individual models
of physiotherapy following intramuscular lower limb
BoNT-A injections for ambulant children with CP. To our
knowledge, this will be the first study to compare these
two physiotherapy models with this population using out-
come measures across domains of the ICF. It will address
the essential need for rehabilitation services to consider
flexible models of service delivery in response to family
preferences and an increasing emphasis on improving
goal-directed functional activity performance and societal
participation within a family-centred framework [94]. Im-
portantly, children, caregiver/s and therapists will have a
greater informed choice of post BoNT-A rehabilitation
delivery options.
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